FDA 483 - Matthew A. Cunningham, M.D. - April 18, 2025

An FDA inspection of Florida Retina Institute, a clinical investigator in Orlando, FL, revealed significant deficiencies in the conduct of a clinical investigation. Observations included failures to follow the investigational plan, improper documentation of informed consent, and inadequate maintenance of case histories. These issues indicate a lack of adherence to regulatory requirements for clinical trials.